We next evaluated whether FZD6 knockdown enhances the therapeutic effect of cisplatin toward advanced human prostate cancers in vivo using the LuCaP35CR CRPC model that we have engineered to express the doxycycline inducible FZD6 shRNA. This evidence concerns the gene FZD6 and prostate carcinoma.